In this completed Phase 2 study, brilaroxazine met all safety endpoints with no weight gain, no increase in blood sugar and lipids, and no cardiac or endocrine adverse effects compared to placebo.
6 Likes
The small company has only one Phase 3 trial running and limited capital. I hope the Phase 3 results are good enough for an NDA.
4 Likes
The next step is to manufacture antipsychotics that do not act directly or indirectly (as utaront and karxt do) on the dopaminergic system. That will be the “big” breakthrough.
3 Likes